8th AnnualInvitation Only
MPN-MDS
USFocus Meeting 2027
Two days, 62 people, one room.
April 9 to 10, 2027
Nashville, TN
Dates
April 9-10, 2027
Two-day program
Venue
Nashville, TN
Hotel TBC
Audience
62 by invitation
31 KOLs & 31 fellows
Format
9 sessions · 32 talks
Keynotes, panels + debates
A Curated Room: The People Shaping Practice
This 8th annual, invitation-only meeting convenes a deliberately small faculty: 31 leading MPN and MDS KOLs alongside 31 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The science tracks where treatment is moving: mutant CALR and next-generation JAK2 targeting, new options in PV, rational frontline combinations in MF, and molecularly defined MDS from TP53 to IDH. Sessions pair expert talks with a moderated panel, and each day opens with a keynote and a Rising Stars debate, sustained, close-quarters engagement rather than a lecture hall.
Mutant CALR TargetingNovel MF CombinationsRopeg & Rusfertide in PVLR-MDS & EMAsHR-MDS · TP53 · IDHMPN · MDS · MDS/MPN
Meeting Co-Chairs
Prithviraj Bose
MD Anderson Cancer Center, Houston, TX
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Faculty Drawn From
MD Anderson · Moffitt · Memorial Sloan Kettering · Johns Hopkins · Yale · Fred Hutch and other leading US cancer centers
62
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
MPN-MDS US Focus Meeting 2027
Faculty
Listed alphabetically by surname
Hussein Abbas
MD Anderson Cancer Center, Houston, TX
Uma Borate
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Prithviraj Bose
MD Anderson Cancer Center, Houston, TX
Naval Daver
MD Anderson Cancer Center, Houston, TX
Amy DeZern
Johns Hopkins Medicine, Baltimore, MD
Guillermo Garcia Manero
MD Anderson Cancer Center, Houston, TX
Anthony Hunter
Winship Cancer Institute, Emory University, Atlanta, GA
Elias Jabbour
MD Anderson Cancer Center, Houston, TX
Tapan Kadia
MD Anderson Cancer Center, Houston, TX
Hagop Kantarjian
MD Anderson Cancer Center, Houston, TX
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Andrew Kuykendall
Moffitt Cancer Center, Tampa, FL
Sanam Loghavi
MD Anderson Cancer Center, Houston, TX
Yazan Madanat
UT Southwestern Medical Center, Dallas, TX
Lucia Masarova
MD Anderson Cancer Center, Houston, TX
Ruben Mesa
Atrium Health, Charlotte, NC
Alain Mina
Yale School of Medicine, New Haven, CT
Stephen Oh
Washington University School of Medicine, St. Louis, MO
Eric Padron
Moffitt Cancer Center, Tampa, FL
Naveen Pemmaraju
MD Anderson Cancer Center, Houston, TX
Uday Popat
MD Anderson Cancer Center, Houston, TX
Raajit Rampal
Memorial Sloan Kettering Cancer Center, New York, NY
Lindsay Rein
Duke Cancer Institute, Durham, NC
David Sallman
Moffitt Cancer Center, Tampa, FL
Michael Savona
Vanderbilt University Medical Center, Nashville, TN
Bart Scott
Fred Hutchinson Cancer Center, Seattle, WA
Mikkael Sekeres
University of Miami Miller School of Medicine, Miami, FL
Pankit Vachhani
UAB Medicine, Birmingham, AL
Zhuoer Xie
Moffitt Cancer Center, Tampa, FL
Abdulraheem Yacoub
University of Kansas Medical Center, Kansas City, KS
Amer Zeidan
Yale School of Medicine, New Haven, CT
Two Days, Nine Sessions
Agenda
Presentations15 min
Panel Discussions30 min
Lunch50 min
20 min
65 min
Day One · Friday, April 9, 2027
Keynote Lecture 1: The Future of MPN Management
Ruben MesaAtrium Health, Charlotte, NC
Rising Stars Debate 1: MPN
2 fellows / junior faculty debate
Session ISetting the Stage
Moderator
Myeloid Neoplasms Classification from the Microscope to Clinic
Sanam LoghaviMD Anderson Cancer Center, Houston, TX
The Chicken and the Egg: Clonal Hematopoiesis and Inflammation in MDS
Zhuoer XieMoffitt Cancer Center, Tampa, FL
MPN Translational Topic: TBD
Prithviraj BoseMD Anderson Cancer Center, Houston, TX
Session IIPV
Moderator
Revisiting Risk Stratification in PV – Isn’t It About Time?
Andrew KuykendallMoffitt Cancer Center, Tampa, FL
Ropeg and Rusfertide – Fight or Join Forces?
Naveen PemmarajuMD Anderson Cancer Center, Houston, TX
Rux and Emerging JAK2 Inhibitors for PV
Prithviraj BoseMD Anderson Cancer Center, Houston, TX
Session IIIET and CML
Moderator
Inhibiting Mutant CALR: Ushering in a New Era of Molecularly Targeted Therapy in ET
Lucia MasarovaMD Anderson Cancer Center, Houston, TX
Ropeg Now Approved for ET: Review of the Evidence and Implications for the Future
Abdulraheem YacoubUniversity of Kansas Medical Center, Kansas City, KS
CML 2027 Primer
Elias JabbourMD Anderson Cancer Center, Houston, TX
Session IVMyelofibrosis
Moderator
Frontline Rational Combos in MF and the Need for New Endpoints
Pankit VachhaniUAB Medicine, Birmingham, AL
AJ1-11095 and INCA033989: Game Changing Treatments for MF or Too Soon to Tell?
Raajit RampalMemorial Sloan Kettering Cancer Center, New York, NY
Anemia in MF – Still an Unmet Need?
Stephen OhWashington University School of Medicine, St. Louis, MO
Transplant for MF – Still the Only Potential Cure
Uday PopatMD Anderson Cancer Center, Houston, TX
Special Interest in MPN
Management of Accelerated and Blast Phase MPN
Tapan KadiaMD Anderson Cancer Center, Houston, TX
Day Two · Saturday, April 10, 2027
Keynote Lecture 2: Moving Towards the Cure in MDS and AML
Hagop KantarjianMD Anderson Cancer Center, Houston, TX
Rising Stars Debate 2: MDS
2 fellows / junior faculty debate
Session VAtypical MPN and MDS/MPN
Moderator
Systemic Mastocytosis Comes of Age
Lindsay ReinDuke Cancer Institute, Durham, NC
Primer on Eosinophilia
Hussein AbbasMD Anderson Cancer Center, Houston, TX
CMML
Eric PadronMoffitt Cancer Center, Tampa, FL
Other MDS/MPN Overlap Syndromes
Anthony HunterWinship Cancer Institute, Emory University, Atlanta, GA
Session VILower Risk MDS
Moderator
EMAs in Lower Risk MDS
Amer ZeidanYale School of Medicine, New Haven, CT
Telomerase Inhibition in LR-MDS
Michael SavonaVanderbilt University Medical Center, Nashville, TN
How I Sequence Therapies in LR-MDS
Yazan MadanatUT Southwestern Medical Center, Dallas, TX
Novel Agents in LR-MDS
Mikkael SekeresUniversity of Miami Miller School of Medicine, Miami, FL
Session VIIHigher Risk MDS
Moderator
Management of Higher Risk MDS
Guillermo Garcia ManeroMD Anderson Cancer Center, Houston, TX
Novel Agents in Higher-Risk MDS
Alain MinaYale School of Medicine, New Haven, CT
Transplant for MDS
Bart ScottFred Hutchinson Cancer Center, Seattle, WA
AML Upfront Management in 2027
Naval DaverMD Anderson Cancer Center, Houston, TX
Special Interest in MDS
Moderator
TP53 Myeloid Neoplasm
David SallmanMoffitt Cancer Center, Tampa, FL
IDH Myeloid Neoplasm
Rami KomrokjiMoffitt Cancer Center, Tampa, FL
Aplastic Anemia and Bone Marrow Failure Syndromes
Amy DeZernJohns Hopkins Medicine, Baltimore, MD
CHIP and CCUS Updates
Uma BorateThe Ohio State University Comprehensive Cancer Center, Columbus, OH
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
Your Point of Contact
Zeynep Aydagül
Account Executive, MD Education
zeynep.aydagul@md-education.com